Dominique Verhelle is a Senior Director, Strategic Academic Alliances, Center for External Innovation at Takeda. She is responsible for initiating and developing Research Alliances with Academic Institutes. She is playing a major role in identifying investigators whose research is at the cusp of innovation which in partnership with Takeda develop new therapeutics for patients.
Before that, Dominique was a principal at Third Rock Ventures for 2 years and a half. She joined in 2015 as a strategic advisor to focus on drug discovery and development across the portfolio. She played an instrumental role in the creation of Fulcrum Therapeutics, a portfolio company launched in 2016 and Cedilla Therapeutics launched in April 2018.
Dominique has more than 20 years of R&D experience, principally in oncology. From 2012 to 2015, she was a Director at Pfizer in the Oncology Research Unit; there she created and led the Epigenetic Department. Prior to that, she was a Group Leader at Celgene. From 2003 to 2012, she contributed to the understanding of the mechanism of action of IMiDs and later on initiated the epigenetic effort with the creation and the leadership of the internal scientific group and partnership / M&A initiatives.
Dominique completed her postdoctoral training in the laboratory of Dr. Christopher Glass at University of California, San Diego focusing on transcription regulation and chromatin remodeling. She holds a Ph.D. in Life Sciences from the University of Nice-Sophia-Antipolis, France and an MBA in Entrepreneurships from the Rady School of Management, University of California, San Diego.